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Purpose: To evaluate the effectiveness of 18F-Fluorodeoxyglucose positron emission
tomography/computed tomography (18F-FDG-PET/CT) for detecting early cancer in carri-
ers of germline TP53 mutation, the genetic defect underlying Li-Fraumeni and related
syndromes, which predisposes to many forms of cancer throughout life.
Patients and methods: A total of 30 adult patients from six families with germline
TP53 mutations were recruited. These patients did not have a diagnosis of cancer in
the 24 months preceding the study. Anomalous concentrations from whole-body 18F-FDG-
PET/CT were assessed by two independent experts. Suspicious lesions were excised and
subjected to pathological examination.
Results: A total of 6/30 patients showed abnormal 18F-FDG-concentration. Confirmation
studies revealed three cases of cancer, including one lung cancer, one ovarian cancer, and
one disseminated breast cancer.Three patients had non-malignant lesions (one Bartholin’s
cyst and two cases of reactive lymph nodes).
Conclusion: 18F-FDG-PET/CT is effective in detecting cancer in subjects who are asymp-
tomatic according to current screening guidelines. These results further suggest that
18F-FDG-PET/CT is an appropriate method for surveillance of cancer risk in TP53 mutation
carriers.
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INTRODUCTION
Li-Fraumeni syndrome (LFS) is an autosomal-dominant hered-
itary cancer predisposition syndrome associated with germline
mutations in the tumor suppressor gene TP53 (1, 2). TP53 muta-
tion carriers have a 50% risk for development of a wide spectrum
of malignant tumors by age 30 (3). Several clinical definitions
of LFS have been proposed, identifying incomplete forms termed
Li-Fraumeni-like (LFL) (4, 5). According to current recommen-
dations (6), referral of a subject for TP53 mutation testing should
be considered if: (i) a proband with a typical LFS/LFL tumor
(soft-tissue sarcoma, osteosarcoma, brain tumor, pre-menopausal
breast cancer, adrenocortical carcinoma, leukemia, or bronchiolo-
alveolar carcinoma) before 46 years with at least one first or
second-degree relative with a LFS/LFL tumor before age 56; (ii) a
proband with multiple tumors, two of which belong to LFS spec-
trum and the first one diagnosed before age 46; (iii) a proband
with adrenocortical carcinoma or choroid plexus tumor irrespec-
tive of family history (7). Germline TP53 mutations are detected
in 29% of the cases fulfilling these criteria (6).
The clinical heterogeneity of LFS raises complex challenges
for the management of cancer risk. The guidelines of the
National Comprehensive Cancer Network (NCCN) propose a risk
management strategy based on clinical examination and imag-
ing with ultrasonography, mammography, and nuclear magnetic
resonance imaging (MRI) for breast cancer and colonoscopy for
colorectal cancer. Recently, a surveillance protocol based on these
principles has shown efficacy in reducing cancer mortality of TP53
germline mutations carriers (8). This protocol includes additional
intensive screening strategies in children such as rapid whole-body
MRI, brain MRI, abdominal ultrasound examination, and bio-
chemical test for markers of adrenal cortical function (8). However,
this strategy addresses only some of the many cancer types that
may occur in LFS families. Thus, alternative screening methods are
needed, that may detect a larger spectrum of LFS cancers. A pilot
study of screening with 18F-Fluorodeoxyglucose positron emis-
sion tomography/computed tomography (18F-FDG-PET/CT) has
been reported in 15 adult carrying germline TP53 mutations (9).
This study detected three prevalent cases of malignant lesions
(20%), suggesting that 18F-FDG-PET/CT may help in improving
surveillance of cancer risk in LFS/LFL.
In the present study, we describe the use 18F-FDG-PET/CT
for cancer detection in 30 clinically asymptomatic TP53 mutation
carriers undergoing continuous follow-up according to NCCN
guidelines (2009 version) and with no diagnosis of cancer within
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2 years preceding the study. The study was conducted in a popu-
lation of patients from Southern Brazil, where LFS is particularly
common due to a founder TP53 mutation, p.R337H (7).
MATERIALS AND METHODS
PATIENTS AND SELECTION CRITERIA
Institutional Review Board approval was obtained and all patients
included in this study provided informed consent. Thirty patients
who carried aTP53 germline mutation were selected at the Depart-
ment of Oncogenetics, Hospital A.C. Camargo, São Paulo, Brazil.
Individuals who fulfilled criteria for TP53 mutation testing were
included. Upon positive testing, a total of 30 subjects were con-
secutively recruited. All patients matched clinical criteria for LFS
or LFL (Table 1) and were not diagnosed with cancer within
2 years preceding inclusion in the study. Exclusion criteria were
age under 18, refusal to participate in the study, and history of
metastatic cancer. The study was carried out from March 2009 to
March 2011.
18F-FLUORODEOXYGLUCOSE POSITRON EMISSION
TOMOGRAPHY/COMPUTED TOMOGRAPHY
18F-FDG-PET/CT whole-body scans were performed at the
Nuclear Medicine division of the Imaging Department, Hospital
A.C. Camargo, with PET-CT GEMINI Philips equipment. Patients
were fasting for 6 h before undergoing examination. Venous injec-
tion of 5.2 MBq/Kg of 18F-FDG was performed after a 30-min rest
and blood glucose level verification. The examination protocol
started with no contrast CT and was followed by the PET acqui-
sition, from the head up to the medium third of the thigh 90 min
after injection. Images were analyzed and interpreted by one of
three nuclear physicians and confirmed by a second. The criteria
used for evaluation of the examinations were the existence of visu-
ally abnormal sites of 18F-FDG concentration and the quantitative
measurement of the standardized uptake value (SUV).
RESULTS
A total of 30 patients were included (18 women, 12 men; mean age:
43± 16.5 years; age range, 19–76 years), representing a total of six
families with a diagnosis of LFS or LFL syndrome. The Brazil-
ian founder p.R337H TP53 mutation was present in 90% of the
patients (27/30, belonging to four apparently unrelated families).
Prior to testing for TP53, all patients were already under surveil-
lance according to NCCN guidelines (10), based on their familial
history. None of them showed signs of cancer disease.
Sites with abnormal concentration of 18F-FDG were observed
in 20% (6/30) of the patients (Table 2). Among the six patients,
findings were further assessed using conventional imaging and/or
histopathology. One lesion was identified in a pelvic location as
Bartholin’s cyst and patient was returned to clinical follow-up
according to NCCN guidelines (10). The second case was a woman
aged 40 from a family with the mutation p.R337H (shown in
Figure 1, where the patient is identified by an arrow). This patient
had previous history of breast cancer at age 38. 18F-FDG-PET/CT
images were suggestive of diffuse bone (intramedullary) and liver
dissemination of an invasive ductal breast carcinoma (Figure 2).
The lesions were not assessed by pathological examination (PE).
Of note, this patient underwent chest CT and whole-body bone
Table 1 | Families, mutations, and diagnosis criteria for patients
recruited for 18F-FDG PET-CT imaging.
Family Mutation Number of
patients
Diagnosis
criteriaa
cDNA
position
Y12 p.R337H 23 LFS c.1010G>A
Y27 p.R337H 1 LFL(B) c.1010G>A
Y99 p.R337H 2 LFL(C) c.1010G>A
Y97 p.R337H 1 LFS c.1010G>A
Y79 p.T125T 2 LFL(C) c.375G>A
Y131 IV8+G>A 1 LFS (Intronic)
aFamilies were classified according to the clinical definitions of Li-Fraumeni syn-
drome (LFS, proband with sarcoma at 45 years and a first-degree relative with
tumor at 45 and another close relative with tumor at 45, or sarcoma at any age) or
Li-Fraumeni-like syndromes; LFL(B), proband with any childhood cancer or sar-
coma, brain tumor or adrenocortical carcinoma at 45 years, with one first- or
second-degree relative with typical LFS cancer, including sarcoma, breast can-
cer, brain tumor, leukemia, or adrenocortical carcinoma at any age, plus one first-
or second-degree relative in the same lineage with any cancer diagnosed under
age 60; LFL(C), proband with tumor belonging to LFS tumor spectrum (soft-tissue
sarcoma, osteosarcoma, brain tumor, pre-menopausal breast cancer, adrenocor-
tical carcinoma, leukemia, lung bronchoalveolar cancer) before age 46 years and
at least one first- or second-degree relative with LFS tumor (except breast can-
cer if proband has breast cancer) before age 56 years or with multiple tumors;
or proband with multiple tumors (except multiple breast tumors), two of which
belong to LFS tumor spectrum and first of which occurred before age 46 years;
or patient with adrenocortical carcinoma or choroid plexus tumor, irrespective of
family history.
scintillography 1 month before 18F-FDG-PET/CT, with no signs
of metastasis.
Lesions in the four remaining patients were submitted to biop-
sies. In two patients, lesions were confirmed as malignant tumors
by PE (Table 2). An apical left lung lesion was detected in a woman
aged 67 with a history of bilateral breast cancer at 51 and 61 years,
thyroid cancer at 62, and non-melanoma skin cancer at 65, PE
revealed a mixed invasive adenocarcinoma with acinar and lepidic
histological features. The patient was staged as IIIB (Figure 3). She
underwent standard chemotherapy and was in remission 1 year
after diagnosis. She relapsed 24 months post-diagnosis, with devel-
opment of brain metastases. Another patient aged 62 years with
no previous history of malignant disease presented with con-
centrations of 18F-FDG in the abdominal and pelvic area that
identified a pelvic mass, peritoneal carcinomatosis, and multiple
peri-bowel and peri-hepatic implants. PE confirmed the diagno-
sis of undifferentiated carcinoma with probable ovarian origin,
stage IV. Among the two remaining patients, one presented with
a remarkably high 18F-FDG concentration at the mesenteric root
and the other showed an axillary lesion. In both cases, biopsies
revealed a non-malignant hyperplasia of lymph nodes, of probable
reactive origin.
The 27 patients with negative 18F-FDG-PET/CT status or with
non-malignant findings were returned to surveillance accord-
ing to NCCN guidelines. In summary, 18F-FDG-PET/CT imag-
ing detected malignant lesions in 3 of 30 patients who were
non-symptomatic in screening according to NCCN guidelines.
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Table 2 | Characteristics of patients with positive FDG-PET/CT findings.
Patient
number
Gender/
age
Previous history of cancer (age) Concentration
area
TP53
mutation
SUV
max
Histopathological or imaging diagnosis
04 F/67 Breast (51, 61); thyroid (62); skin (65) Lung p.R337H 1.7 Mixed acinar/bronchiolo-alveolar carcinoma
11 F/62 No Pelvis p.T125T 5.1 Adenocarcinoma of the ovary
07 F/40 Breast (38) Bones/liver p.R337H 5.8 Metastases of breast cancer
01 F/29 No Pelvis p.R337H 2.02 Bartholin cyst
16 F/60 No Mesenteric root p.T125T 7.0 Lymph nodes; reactive hyperplasia
20 M/56 Thyroid (54) Right axillary p.R337H 2.0 Single lymph node; reactive hyperplasia
F, female; M, male.
FIGURE 1 | Pedigree of familyY0029. The index patient is indicated by an arrow. Full boxes/circles: patient affected by a malignant tumor. Age of onset and
tumor type are given below each patient’s symbol.
FIGURE 2 | Anomalous concentration of 18F-FDG in index patient of familyY0029. Left panel: anomalous signal in bone projections of bone corresponding
to predominantly intramedullary lesions. The arrow points to a lesion with SUV 5.80. Right panel: anomalous signal in the liver. The arrow points to a lesion with
SUV 2.13.
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FIGURE 3 | Image fusion of PET with CT showing anomalous
concentration of 18F-FDG. A lesion localized in the apical pulmonary region
is shown (SUV 1.76).
DISCUSSION
The surveillance of patients with germlineTP53 mutations is com-
plex due to the wide range of cancer types related to LFS, as well
as to lifelong predisposition to cancer. The NCCN guidelines for
patient surveillance recommend follow-up using a combination of
clinical examination, breast imaging, and colonoscopy (10). How-
ever, there is concern that this panoply is insufficient to capture at
an early stage the wide range of malignant lesions these patients
may develop.
In the present study, we have used 18F-FDG-PET/CT to mon-
itor the status of 30 germline TP53 mutation carriers from six
independent families who met at least one of the diagnosis crite-
ria of LFS/LFL. We found anomalous 18F-FDG concentration in
6/30 subjects with germline TP53 mutation (20%). Further inves-
tigation confirmed malignant lesions in 3/30 subjects (10%). Our
results suggest that 18F-FDG-PET/CT is an appropriate means for
surveillance of cancer risk in TP53 mutation carriers.
All patients were included in routine LFS/LFL follow-up
according to NCCN guidelines and did not show evidence of
cancer at the time of enrollment in the study. Our results are
compatible with those of the previous study by Masciari et al. (9),
who analyzed by 18F-FDG-PET/CT a group of 15 TP53 mutation
carriers (or obligate carriers) with no diagnosis of cancer within
5 years prior to recruitment. They found malignant lesions in three
of them (20%) (two cases of thyroid cancer, stages II and III, and
one case of adenocarcinoma of the esophagus, stage II). These
authors also detected areas of abnormal 18F-FDG concentration
in five patients, who were found to correspond to non-malignant
lesions. Thus, together with these previous results, our study pro-
vides evidence for the usefulness of 18F-FDG-PET/CT for cancer
surveillance in LFS/LFL.
The analysis of cumulative rates of occurrence of cancers in
TP53 mutation carriers compiled in the IARC TP53 database
(http://www-p53.iarc.fr) (11) suggests that, in adulthood, between
1 and 2% of mutation carrier develop cancer by each year of
age. Our results and those of Masciari et al. (9) identified that
10 and 20%, respectively, of the subjects had a prevalent cancer.
This observation suggests that malignant lesions in TP53 muta-
tion carriers may occur at a higher rate than expected on the basis
of the data compiled in the IARC database. Further studies on the
risk of cancer per year of age inTP53 mutation carriers are needed
to understand this discrepancy.
It is striking to note that the malignant lesions detected in our
study were all at advanced stage. Thus, this observation raises the
question of whether 18F-FDG-PET/CT is adequate for detection
of early lesions in TP53 mutation carriers. Moreover, it suggests
that, in order to be effective, 18F-FDG-PET/CT should be repeated
at relatively short time intervals of approximately 1 year. Such a
strategy would raise a number of questions with respect to cost-
effectiveness and, in particular, to the need of limiting exposure to
ionizing radiation in patients with germline TP53 mutations (12).
Common practice discourages the use of radiation in LFS/LFL sub-
jects because they are at risk for the development of second malig-
nancies (13). To date, there is no evidence that 18F-FDG-PET/CT
levels of radiation may represent an additional risk factor in
TP53 germline mutation carriers. However, this question deserves
careful, further assessment of the exact nature and level of the risk.
Several groups have begun to utilize an intensive screening
strategy including rapid whole-body MRI, that may not be avail-
able at many centers. Prospective studies are needed to demon-
strate the effectiveness of this protocol in adults and children
with LFS.
In conclusion, our results add to previous data suggesting that
18F-FDG-PET/CT may be an appropriate means for surveillance
of cancer risk in TP53 mutation carriers. They also suggest that
the use of 18F-FDG-PET/CT in research programs is warranted to
gain a better understanding of the risk of developing cancer and
of the actual rate of cancer development in carriers of TP53 muta-
tions. Further studies are needed to assess the conditions of use of
18F-FDG-PET/CT in LFS/LFL surveillance strategies and compare
with other whole body modalities as whole body enhanced CT and
whole body MR with diffusion.
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